[word=and] [tag=VBD] | □
[word=and] [tag=VBD] | [□]
[word=and] [tag=VBD] | □?
SNP arrays are commonly used for mapping new markers of genetic disease and for detecting LOH in cancer . The third sensitivity analysis assessed " sponsor-related physician bias " by including the new covariate just described : the time elapsed between medication initiation and the patient 's enrollment date in the study . Insert , SEM cross section of the shell , revealing the calcitic prismatic layer ( c / pr ) and the inner aragonitic nacreous layer ( a / nc ) . We hypothesized that if " sponsor-related physician bias " were present , physicians would have quickly switched patients from their current antipsychotic to olanzapine rather than to risperidone ( olanzapine , risperidone , and clozapine were available for all patients at the time of enrollment , unlike quetiapine and ziprasidone that were not yet available to early study enrollees ) . Collagen morphology and the epithelial-stromal interaction in the mammary gland . This set of 13 Proteobacterial species comprises a new phylogenetic profile . We aligned these candidate sequences from complete genomes , constructed an HMM , performed a new search , and proceeded iteratively , resulting in TIGR02602 . As shown in Figure 2 , a typical full cytopathic effect of MHV 68 was observed in the control infected cell culture treated with DMSO ; most adherent cells become detached from the plate , and remaining loosely adhered cells were round and denser than uninfected controls . Results were essentially unchanged when the Cox Proportional Hazards regression model was repeated ( a ) using 1 medication episode per patient ( n = 1028 ) , the one with which the patient was treated first , ( b ) using 1703 treatment episodes , including episodes where patients simultaneously initiated 2 or more treatment episodes , ( c ) using the time elapsed between medication initiation and patients ' enrollment in the study , as a proxy for potential " sponsor-related physician bias , " ( d ) using a medication gap > 14 days to assess robustness of the > 30-day medication gap used to signal medication discontinuation , and ( e ) using ITT analysis , with 2488 treatment episodes , thus not requiring initiators to have continued in the study for at least 1 year following medication initiation .